Diagnosis and treatment of follicular lymphoma: an update.

Mario Bargetzi, Reto Baumann, Sergio Cogliatti, Pierre-Yves Dietrich, Michel Duchosal, Jeroen Goede, Felicitas Hitz, Carolin Konermann, Andreas Lohri, Ulrich Mey, Urban Novak, Alexandros Papachristofilou, Frank Stenner, Christian Taverna, Thilo Zander, Christoph Renner

Journal: Swiss medical weekly 2018;148():w14635

PMID: 30044476

Free Full Text on Bern Open Repository and Information System View on PubMed

Abstract

Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to established regimens such as radiotherapy and immunochemotherapy, new treatment options are on the horizon. Furthermore, even the use of established chemotherapy agents has evolved, with new combinations moving to the forefront of the current treatment strategy. Nevertheless, there remains an unmet need for patients who have early relapses, those who are not responsive to anti-CD20 treatment regimens and for those in whom minimal residual disease persists even after immunochemotherapy. This review provides a summary of current developments in the diagnosis, treatment and management of follicular lymphoma, focusing on the clinical issues from a Swiss perspective.

Address: Oncology-Haematology, Kantonsspital Aarau, Switzerland.; Roche Pharma (Schweiz) AG, Reinach, Switzerland.; Institute of Pathology, Kantonsspital St Gallen, Switzerland.; Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.; Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.; Oncology and Haematology, Kantonsspital Winterthur, Switzerland.; Oncology-Haematology, Kantonsspital Baselland, Liestal, Switzerland.; Oncology and Haematology, Kantonsspital Graubuenden, Chur, Switzerland.; President of the SAKK Project Group Lymphoma, Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.; Radio-Oncology, Universitätsspital Basel, Switzerland.; Department of Oncology, Universitätsspital Basel, Switzerland.; Oncology, Kantonsspital Münsterlingen, Switzerland.; Department of Oncology, Luzerner Kantonsspital, Luzern, Switzerland.; Onkozentrum Hirslanden & Zürich, Zürich, Switzerland.

DOI: 10.4414/smw.2018.14635

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/30044476

MeSH Terms: Antineoplastic Agents, Alkylating, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Combined Modality Therapy, Disease Management, Humans, Immunotherapy, Lymphoma, Follicular, Neoplasm Grading, Positron Emission Tomography Computed Tomography, Quality of Life, Recurrence, Rituximab, Survival Rate